Caly, L., Druce, J.D., Catton, M.G., et al. (2020) The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 in Vitro. Antiviral Research, 178, Article ID: 104787.
https://doi.org/10.1016/j.antiviral.2020.104787

has been cited by the following article:

• TITLE: Case Report: Successful Post-COVID Severe Peripheral Polyneuropathy Treatment Post AZD1222 ChAdOx1 SARS-CoV-2 Vaccination

  AUTHORS: Paulo Macio Porto de Melo, Rute Alves Pereira e Costa

  KEYWORDS: COVID-19, Vaccines, Case Report, Corticosteroids, Testosterone, Ivermectin

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.11 No.5, May 13, 2022

  ABSTRACT: Background: The condition known as polyneuropathy causes peripheral nerve disability, and is characterized by symmetrical distal numbness and paresthesia, often accompanied by pain and weakness. With the advancement of the pandemic in Brazil and in the world, the need for therapies as well as prophylaxis became the main focus in disease control as the viral vector platform vaccine AstraZeneca. Some effects were observed over the period of application. Case Summary: A male patient, 63 years old, previously vaccinated for COVID-19, developed active infection by the virus and in his convalescent period presented intense weakness, with prejudice to his daily activities, including personal hygiene ones. Conclusion: The patient made a complete recovery after combination therapy with testosterone derivates, ivermectin, corticosteroids, and vitamins, besides rehabilitation.